Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.
Poster Apr 01, 2014
Bavykin A.S.1, Korotaeva A.A.1, Poyarkov S.V.2, Syrtsev A.V.1, Karpukhin A.V.1
Results. We found that colon cancer cells HCT-116, when exposed to low concentrations of oxaliplatin (5 and 10mkM) showed the the same survival rate as for the untreated cells, however their expression patterns were different. We examined the panel of genes with various functions in the presence of small dozes of oxaliplatin and picked up those, that displayed marked overexpression and were depended both on the oxaliplatin dose escalation and the incubation period. These genes belong to the family of inhibitors of apoptosis and associated with the caspase cascade. Shutting down the expression of these genes was performed using short interfering RNAs (siRNAs), attached to the liposome particles. These ultra – small molecules can suppress synthesis of desired proteins at the level of messenger RNA of Birc3 and Birc7 genes. Due to the ultra small size, and low concentration, that is sufficient enough to inhibit protein synthesis at an early stage. Thus siRNA have considerable advantages compared with targeted antibodies.
Conclusion. Identified target genes Birc3 and Birc7 display specific response to oxaliplatin treatment. Joint inhibiting the synthesis of these genes resulted in virtually complete (85%, p<0,05) suppression of the viability of cancer cells and increased (7-fold) sensitivity of cancer cells to low doses of oxaliplatin.
Basic fibroblast growth factor (bFGF) is widely used in vitro for the maintenance and stimulation of a variety of cells. However, use of native bFGF in cell biology is limited by the fact that bFGF rapidly degrades at physiological temperatures. We have addressed this problem with an engineered form of bFGF, named Heat Stable bFGF (HS bFGF), which is stable at 37 degrees Celsius.READ MORE